Stanley Ho Centre for Emerging Infectious Diseases
Shatin, Hong Kong
NCT Number: NCT06188442
The goal of this clinical trial is to compare the effectiveness of doxycycline taken for on-demand pre-exposure prophylaxis (DoxyODPrEP) and its post-exposure use (DoxyPEP) in preventing bacterial sexually transmitted infections (STI), including chlamydia, gonorrhoea, and syphilis among men who have sex with men (MSM). The main questions it aims to answer are:
1. Is DoxyODPrEP superior to DoxyPEP? 2. Are both regimens safe? 3. Does the MSM community accept the use of doxycycline to prevent bacterial STI?
Participants will be asked to take doxycycline according to the study arm they are randomly assigned to, and attend regular clinical follow-ups during the 2-year observation period. Researchers will compare the bacterial STI incidences between the two groups to see if DoxyODPrEP is superior to DoxyPEP.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
Male
Interventional
Phase 4
Shatin, Hong Kong
Participants would be randomly assigned to either DoxyODPrEP or DoxyPEP arm, and be instructed to take doxycycline with the respective dosing schedule. They would be followed up for 24 months for nucleic acid amplification test (NAAT) and antibody tests against bacterial STI, namely chlamydia, gonorrhoea, and syphilis. The subjects and investigators would not be blinded due to its open-label nature, as the two arms' dosing schedules are different. Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex. Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex. At each clinic visit, urine, and pharyngeal and rectal swabs would be self-collected on-site by the participants following instructions. Pill count would be performed for each follow-up visit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
Other names: doxycycline on demand PrEP
Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
Other names: doxycycline PEP
Time frame: Months 1 to 24
Time to the first episode of gonorrhoea after the enrolment visit
Time frame: Months 1 to 24
Time to the first episode of chlamydia after the enrolment visit
Time frame: Months 1 to 24
Time to the first episode of syphilis after the enrolment visit
Time frame: Months 1 to 24
Percentage of participants experiencing adverse events and the associated grades
Time frame: Months 1 to 24
Percentage of participants accepted the regimen
Time frame: Months 1 to 24
Percentage of participants remained during the follow-up period
Time frame: Months 1 to 24
Time to the first episode of HIV after the enrolment visit
Chinese University of Hong Kong
Other
Superiority of On-demand Pre-exposure Prophylaxis Versus Post-exposure Prophylaxis on Using Doxycycline for Preventing Sexually Transmitted Infections in Men Who Have Sex With Men
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05307991
Bacterial Infections, Bacterial Infections and Mycoses
Lilongwe, Malawi
View Trial DetailsNCT04036396
Bacterial Infections, Bacterial Infections and Mycoses
Los Angeles, California, United States
View Trial DetailsNCT04036318
Bacterial Infections, Bacterial Infections and Mycoses
Shinyanga, Kahama, Tanzania
View Trial DetailsNCT04182230
Antimicrobial Resistance, Bacterial Infections
Llantrisant, United Kingdom
View Trial Details